"What's the buzz, tell me what's happening?"
Tim Rice, “Jesus Christ Superstar”
My friends,
There is a buzz about Optiscan, and it’s getting louder. We are seeing publications on head and neck cancer. There are study results on breast cancer to be released. There is a transformation in management. We are even seeing progress in snail-paced over-bureaucratised medical regulatory processes. Tiresias feels. Tiresias senses. Tiresias knows though that there are some speed bumps on the path. Tiresias is confident that these speed bumps which previous managements failed to negotiate will be overcome. It’s just too big and too important to be otherwise.
Tiresias is too old to be anything but a realist. He understands that everything in this current modern world depends on negotiating the dead-hand of bureaucratic regulations. We are, my friends, in a brave new world of central planning. We see it everywhere, but nothing compared to the regulatory madness in the medical field. Central planning was tried last century and failed. Unfortunately, the west has forgotten this, and is now doubling down on central planning and regulations. Australia my friends, is a poster child and the great exemplar for implementation of the dead-hand of overweening suffocating bureaucracy. But Tiresias has thought and studied. Tiresias has studied the Curriculum Vita of Camile Farah. Tiresias would like to put it on the record, that given Professor Farah’s career trajectory, his qualifications, his experience and publication in pathology and imaging, his industry contacts, Optiscan could not have recruited a better, more qualified, more suited person for the task in hand. That’s right, there is no one, no one in the world, not one person that fits the bill better for Optiscan at this critical and exciting moment. Not only that, Farah has real skin in the game; in what he left to take up this position; the fact he holds shares he bought on his own book prior to coming aboard, and the incentive package which kicks in, at levels which would make us shareholders celebrate to see him rewarded through this package.
Tiresias, please get back the knitting! Ah yes, it’s the technology stupid! Yes of course it is, but it’s also always been the medical market and regulatory environment too, which Optiscan has not been able to deal with in the past. Let us remind ourselves, let us remember and keep repeating it to ourselves, nay, let us shout it and keep shouting it off the rooftops; Optiscan Confocal, fluorescent[WK1] , 3-Dimensional, Laser, Digital, Decentralised, In-Vivo, Real-Time, Artificial Intelligence enabled Microscopy is the next big thing in pathology; in the clinic-based screening and diagnosis of cancers, and in the operating room guidance and monitoring surgical treatment of cancer. Our time is near.
To Quote Tim Rice once again, “When do we ride into Jerusalem?” Tiresias is patient. We are on the right side of medical history.
Add to My Watchlist
What is My Watchlist?
